menu
    • menu
    [{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"RABI-767","moa":"Lipase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Lamassu Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lamassu Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Lamassu Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"SA53","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lamassu Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lamassu Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Lamassu Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SA53-OS","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lamassu Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lamassu Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lamassu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SA53-OS","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lamassu Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lamassu Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lamassu Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Lamassu Pharma

    Menu

    Lamassu Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lamassu Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Lamassu Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SA53-OS

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

                            Details : SA53-OS is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 29, 2024

                            Lead Product(s) : SA53-OS

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lamassu Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Lamassu Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SA53-OS

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves Clinical Trials for Lamassu's Metastatic Cancer Treatment

                            Details : SA53-OS is a genetically targeted therapy that targets the MDM2 protein, a key regulator of the tumor suppressor p53 gene, aiming to induce tumor cell death and inhibit tumor growth.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 11, 2024

                            Lead Product(s) : SA53-OS

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lamassu Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Lamassu Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SA53

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Lamassu Awarded NIH Grant For Breakthrough Cancer Treatment

                            Details : The net proceeds from the funding will be used for the development of SA53, a novel MDM2 inhibitor, for the treatment of p53 wild-type sarcomas, malignant tumor of connective or non-epithelial tissue.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 12, 2024

                            Lead Product(s) : SA53

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lamassu Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Lamassu Pharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RABI-767

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $1.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Lamassu Pharma Receives Prestigious $1.5 Million NIH SBIRP Grant to Support Further Development of its Novel T...

                            Details : The SBIR grant will be used for further development of company's lead therapeutic compound, RABI-767, a novel small molecule lipase inhibitor licensed from the Mayo Foundation for Medical Education and Research.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 14, 2020

                            Lead Product(s) : RABI-767

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $1.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth